ERBB2 and non-small cell lung carcinoma: For instance, in the treatment of NSCLC patients harboring HER2 exon 20 mutations with pyrotinib (as an oral pan-HER TKI), an ORR of 53.3% and a median PFS of 6.4 months with no extreme adverse events have been reported [177].